Plasma Stress Response Biomarkers for Perioperative Optimization

Abstract

The perioperative period is characterized by a dynamic interplay of physiological responses to surgical stress, with significant implications for patient outcomes. Plasma stress response biomarkers have emerged as valuable tools for perioperative optimization, providing insights into the individual patient's stress response, guiding risk stratification, and enabling tailored management strategies. This review synthesizes current evidence regarding key plasma biomarkers, their mechanistic roles in the stress response, and their utility in the perioperative setting. Emphasis is placed on clinical relevance, recent advances, and guideline recommendations to inform best practices for healthcare professionals involved in perioperative care.

Introduction

The surgical stress response is a complex physiological reaction encompassing neuroendocrine, inflammatory, and immune pathways activated by tissue injury, anesthesia, and associated interventions. The magnitude and profile of this response can influence perioperative morbidity and mortality, particularly in vulnerable populations such as the elderly and those with comorbidities. Plasma biomarkers reflecting the acute stress response are increasingly recognized as adjuncts in perioperative risk assessment, early detection of complications, and individualized patient optimization. This article aims to provide a comprehensive overview of plasma stress response biomarkers, their pathophysiological significance, and clinical utility for perioperative optimization.

Epidemiology / Disease Burden

Globally, over 300 million surgical procedures are performed annually, with perioperative complications contributing significantly to morbidity, mortality, and healthcare costs. The burden of adverse outcomes is particularly high among patients with inadequate physiological reserves or exaggerated stress responses. Studies estimate that 10-20% of surgical patients experience major complications, often mediated by dysregulated inflammatory and hormonal responses. Early identification of high-risk individuals through biomarker profiling can facilitate targeted interventions, potentially reducing the incidence and severity of perioperative adverse events.

Pathophysiology

The perioperative stress response is orchestrated by the activation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system, leading to the release of cortisol, catecholamines, and pro-inflammatory cytokines such as interleukin-6 (IL-6) and C-reactive protein (CRP). These mediators coordinate metabolic, cardiovascular, and immune adaptations to surgical insult. However, excessive or prolonged activation can precipitate tissue injury, immunosuppression, and organ dysfunction. Plasma biomarkers such as cortisol, IL-6, CRP, and procalcitonin provide real-time quantification of the magnitude of stress and inflammation, offering mechanistic insights into perioperative risk.

Risk Factors

Several patient-related and procedure-related factors influence the plasma stress response. Advanced age, frailty, obesity, pre-existing cardiopulmonary disease, diabetes, and chronic inflammatory conditions predispose to heightened stress biomarker release. Surgical factors including operative duration, invasiveness, and emergency status further amplify the physiological response. Anesthetic technique, perioperative hemodynamic instability, and inadequate analgesia are additional contributors. Recognizing these risk factors enables clinicians to interpret biomarker levels within the appropriate clinical context and stratify patients for targeted optimization strategies.

Clinical Features

The clinical manifestation of an exaggerated perioperative stress response is variable, ranging from subtle tachycardia and hypertension to overt systemic inflammatory response syndrome (SIRS), delirium, and multi-organ dysfunction. Elevations in plasma biomarkers such as IL-6 and CRP often precede overt clinical deterioration, serving as early warning signals. Persistent elevation of procalcitonin or CRP postoperatively is associated with infectious complications and poor outcomes. Monitoring these biomarkers allows for timely recognition of high-risk trajectories and informs escalation of care.

Diagnosis

Quantitative measurement of plasma stress response biomarkers is achieved through standardized immunoassays and high-sensitivity laboratory techniques. Cortisol, IL-6, CRP, and procalcitonin are the most studied and clinically validated biomarkers in the perioperative context. Baseline and serial postoperative measurements can delineate individual response profiles, facilitate early diagnosis of complications, and guide therapeutic decision-making. Emerging technologies such as multiplex assays enable simultaneous assessment of multiple biomarkers, enhancing diagnostic yield and prognostic accuracy.

Treatment & Management

Optimization of the perioperative stress response involves a multimodal approach integrating surgical, anesthetic, and medical strategies. Preoperative risk assessment using plasma biomarkers informs individualized anesthetic planning, intraoperative hemodynamic management, and postoperative surveillance. Interventions such as enhanced recovery protocols, judicious use of regional anesthesia, and pharmacological modulation of neuroendocrine and inflammatory pathways have demonstrated efficacy in attenuating the stress response. Timely escalation of care based on biomarker trends can mitigate the progression of complications and improve outcomes.

Recent Advances / Emerging Therapies

Recent research has focused on novel plasma biomarkers such as copeptin, suPAR (soluble urokinase plasminogen activator receptor), and presepsin, which offer refined prognostic capabilities in the perioperative setting. Genomic and proteomic approaches are uncovering patient-specific stress response signatures, paving the way for precision medicine in perioperative care. Integration of artificial intelligence and machine learning algorithms with biomarker data holds promise for real-time risk prediction and personalized optimization strategies. Ongoing clinical trials are evaluating the utility of targeted interventions guided by dynamic biomarker monitoring.

Guideline Recommendations

International perioperative guidelines increasingly acknowledge the role of plasma stress response biomarkers in risk stratification and surveillance. The Enhanced Recovery After Surgery (ERAS) Society recommends perioperative biomarker monitoring for high-risk patients undergoing major surgery. Consensus statements from the American Society of Anesthesiologists and the European Society of Anaesthesiology highlight the utility of biomarkers such as IL-6 and procalcitonin in guiding postoperative management. However, standardized protocols for biomarker-driven interventions are evolving, and multidisciplinary collaboration is essential for effective implementation.

Conclusion

Plasma stress response biomarkers represent a transformative advance in perioperative medicine, offering objective, mechanism-based tools for patient optimization. Their integration into clinical practice enables early identification of high-risk patients, individualized management, and improved surgical outcomes. As emerging technologies and evidence advance the field, ongoing research and guideline refinement will further enhance the clinical utility of these biomarkers in perioperative care.